RT Journal Article
SR Electronic
T1 Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6361
OP 6366
DO 10.21873/anticanres.12994
VO 38
IS 11
A1 ELISABETH I. HEATH
A1 LANCE K. HEILBRUN
A1 DARYN SMITH
A1 WILLIAM M. SCHOPPERLE
A1 YAWEN JU
A1 SUSAN BOLTON
A1 QURATULAIN AHMED
A1 WAEL A. SAKR
YR 2018
UL http://ar.iiarjournals.org/content/38/11/6361.abstract
AB Background/Aim: Podocalyxin, a member of the CD34 family of cell surface sialomucins, is overexpressed in human embryonal carcinoma cell lines, as well as in several cancer types, and is associated with poor prognosis. Podocalyxin variants are associated with an increased risk and aggressiveness of prostate cancer. Herein podocalyxin protein expression in prostate cancer was characterized. Materials and Methods: Expression of podocalyxin as well as of TRA-1-60 and TRA-1-81 antigens was assessed immunohistochemically in 84 radical prostatectomy specimens and in adjacent normal tissues. Results: Podocalyxin expression and H-scores were considerably higher in prostate tumors compared to normal tissues. High TRA-1-60 and TRA-1-81 staining was detected, however, in a much smaller percentage of prostate tumors, while their expression and H-scores were low in normal tissues. Similar trends for all three proteins were observed in prostatic intraepithelial neoplasia. Conclusion: Overexpression of podocalyxin in prostate cancer renders the protein a putative immunohistochemical marker of prostate cancer that may contribute to stratification of patients for optimal treatment.